Showing results (1-10 of 172) with videos related to
Sort By:
Pageof 18
Expert Opinion on Pharmacotherapy|June 13, 2017
Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myelomaKlaus Podar, Martin PecherstorferExpert Opinion on Biological Therapy|September 1, 2017
Adoptive cell therapy in multiple MyelomaSonia Vallet, Martin Pecherstorfer, Klaus PodarPharmaceutics|October 26, 2018
Myeloma Bone Disease: Update on Pathogenesis and Novel Treatment StrategiesSonia Vallet, Julia-Marie Filzmoser, Martin Pecherstorfer, et al.Leukemia & Lymphoma|January 19, 2018
A role for bone turnover markers β-CrossLaps (CTX) and amino-terminal propeptide of type I collagen (PINP) as potential indicators for disease progression from MGUS to multiple myelomaSonia Vallet, Nicholas R Hoyle, Robert A Kyle, et al.Expert Opinion on Pharmacotherapy|July 13, 2022
On the continuous (R)evolution of antibody-based and CAR T cell therapies in multiple myeloma: an early 2022 glance into the futureVincent Sunder-Plassmann, Osman Aksoy, Judith Lind, et al.Cancers|January 21, 2023
Evaluation of Antibody Responses in Patients with B-Cell Malignancies after Two and Three Doses of Anti-SARS-CoV-2 S Vaccination-A Retrospective Cohort StudyStella Rosa Maria Wirth, Klaus Podar, Martin Pecherstorfer, et al.Current Cancer Drug Targets|June 8, 2012
Novel targets and derived small molecule inhibitors in multiple myelomaKlaus PodarBMC Cancer|June 29, 2021
Effect of cachexia on bone turnover in cancer patients: a case-control studyHannes Zwickl, Elisabeth Zwickl-Traxler, Alexander Haushofer, et al.Expert Opinion on Pharmacotherapy|October 27, 2004
Efficacy and safety of ibandronate in the treatment of neoplastic bone diseaseMartin PecherstorferPageof 18